StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL – Free Report) from a hold rating to a buy rating in a report issued on Thursday morning. Several other equities analysts have also commented on OMCL. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a neutral […]

Raymond James reaffirmed their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report released on Thursday morning, MarketBeat.com reports. Raymond James currently has a $155.00 price target on the stock. Other equities analysts also recently issued reports about the company. Royal Bank of Canada cut their price objective on Neurocrine […]

Clearside Biomedical (NASDAQ:CLSD – Free Report) had its price objective increased by Needham & Company LLC from $4.00 to $6.00 in a research note published on Thursday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Several other brokerages have also issued reports on CLSD. Chardan Capital started coverage […]

Integra LifeSciences (NASDAQ:IART – Free Report) had its price target reduced by Bank of America from $26.00 to $18.00 in a research report sent to investors on Monday, Benzinga reports. They currently have an underperform rating on the life sciences company’s stock. IART has been the subject of several other research reports. Truist Financial reduced […]

Morgan Stanley lowered shares of Garmin (NYSE:GRMN – Free Report) from an equal weight rating to an underweight rating in a research report sent to investors on Monday, MarketBeat reports. They currently have $138.00 target price on the scientific and technical instruments company’s stock, down from their prior target price of $155.00. Several other research […]

Progressive (NYSE:PGR – Free Report) had its price target increased by JPMorgan Chase & Co. from $242.00 to $251.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have an overweight rating on the insurance provider’s stock. PGR has been the subject of a number of other research reports. Jefferies Financial […]

Guggenheim started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) in a research report released on Monday, Marketbeat reports. The brokerage issued a buy rating and a $20.00 target price on the stock. Several other equities analysts have also commented on the stock. Maxim Group upped their price target on shares of Zevra […]

Cantor Fitzgerald reiterated their overweight rating on shares of Archer Aviation (NYSE:ACHR – Free Report) in a research note published on Monday, Benzinga reports. They currently have a $10.00 price objective on the stock. Other analysts have also recently issued reports about the company. HC Wainwright assumed coverage on Archer Aviation in a research report […]

Bristol-Myers Squibb (NYSE:BMY – Free Report) had its price target lifted by Barclays from $42.00 to $43.00 in a report issued on Monday, Benzinga reports. They currently have an underweight rating on the biopharmaceutical company’s stock. BMY has been the subject of several other research reports. TD Cowen raised their target price on Bristol-Myers Squibb […]

Gordon Haskett began coverage on shares of Foot Locker (NYSE:FL – Free Report) in a report published on Monday morning, Marketbeat reports. The firm issued an accumulate rating and a $27.00 target price on the athletic footwear retailer’s stock. A number of other analysts have also commented on FL. Telsey Advisory Group reaffirmed a market […]

Kontoor Brands (NYSE:KTB – Free Report) had its price target increased by Stifel Nicolaus from $80.00 to $89.00 in a report released on Monday, Benzinga reports. They currently have a buy rating on the stock. Several other analysts have also recently commented on the stock. Barclays raised their price objective on shares of Kontoor Brands […]

Needham & Company LLC reissued their buy rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a report published on Monday, Benzinga reports. Needham & Company LLC currently has a $61.00 price objective on the stock. A number of other analysts have also commented on the stock. Jefferies Financial Group assumed coverage on […]

SharkNinja (NYSE:SN – Free Report) had its target price hoisted by Guggenheim from $100.00 to $120.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. SN has been the subject of several other research reports. JPMorgan Chase & Co. upped their target price on […]